Parkinson’s disease does not always begin with a tremor. Nonmotor symptoms such as reduced sense of smell, constipation, anxiety, fatigue, sleep disturbances, urinary problems, and lightheadedness on standing may appear years or even decades before the characteristic movement symptoms develop.
Study Details
A recent clinical commentary examined the case of a 68-year-old man with progressive constipation, reduced smell, anxiety, fatigue, insomnia, nocturia, weight loss, and dizziness when standing.
Although these symptoms could initially suggest depression, a sleep disorder, or another medical condition, their combined pattern was considered most consistent with a nonmotor presentation of Parkinson’s disease.
The commentary also reviewed research examining how frequently these symptoms occur and whether they can predict the later development of Parkinson’s disease.
Methodology
This was not a clinical trial testing a new treatment. It was an educational clinical review built around a patient scenario.
The author compared the patient’s symptoms with evidence from observational studies, cohort studies, and meta-analyses involving people with Parkinson’s disease or individuals followed before diagnosis.
The evidence focused on symptoms that may occur during the prodromal period, the stage when the disease process may already be developing but classic movement symptoms have not yet appeared.
Key Findings
Reduced sense of smell occurs in more than 90% of people with Parkinson’s disease and may appear before motor symptoms.
Constipation affects approximately half of patients and may precede movement difficulties by decades.
People with constipation had more than twice the odds of subsequently developing Parkinson’s disease compared with people without constipation.
Fatigue occurs in about 50% of people with Parkinson’s disease, although it can have many possible causes.
Sleep disorders affect approximately 90% of patients, with insomnia reported in up to 80%.
In one long-term study, isolated REM sleep behavior disorder progressed to an overt neurodegenerative condition at an estimated rate of 6.3% per year. About 73.5% of participants developed a neurodegenerative syndrome within 12 years.
Urinary symptoms, including nocturia, frequency, and urgency, may reflect dysfunction of the autonomic nervous system.
Lightheadedness when standing may be caused by orthostatic hypotension, another possible sign of autonomic impairment.
What This Means for Patients
Constipation, insomnia, anxiety, fatigue, or reduced smell do not automatically mean that someone has Parkinson’s disease. These symptoms are common and can result from many other conditions.
However, a persistent cluster of symptoms may deserve closer evaluation, particularly when loss of smell occurs alongside constipation, unusual sleep behaviors, urinary changes, or dizziness after standing.
Patients should tell their healthcare provider when these symptoms began, whether they are becoming more frequent, and whether family members have noticed movements or behaviors during sleep.
Earlier recognition may allow clinicians to monitor neurological changes more closely, address individual symptoms, and identify developing motor signs sooner.
Implications for Practice
Primary care clinicians may encounter the earliest signs of Parkinson’s disease long before a patient develops a visible tremor or slowed movement.
A pattern involving anosmia, chronic constipation, REM sleep behavior disorder, autonomic symptoms, anxiety, and fatigue should prompt a broader neurological assessment rather than treating every symptom as an isolated problem.
Clinicians may consider reviewing medication effects, measuring sitting and standing blood pressure, evaluating sleep history, assessing smell changes, and looking for subtle motor findings such as reduced arm swing, rigidity, slowed movement, smaller handwriting, or reduced facial expression.
The evidence does not establish that these symptoms alone can diagnose Parkinson’s disease. Their value lies in recognizing a pattern that may justify longitudinal monitoring or referral to a neurologist.
The Bottom Line
Parkinson’s disease may begin quietly.
For some patients, the earliest clues are not tremors but changes in smell, digestion, sleep, mood, bladder function, blood pressure regulation, and energy.
Recognizing these nonmotor symptoms as part of a possible neurological pattern could help patients reach appropriate evaluation earlier.
A very relevant perspective.
The interesting connection with IVD innovation is that neurological disease is progressively moving from diagnosis based mainly on clinical manifestations toward the combination of clinical phenotype and measurable biological markers.
In Parkinson’s disease, research on α-synuclein seed amplification assays and increasingly accessible biomarker approaches may eventually help identify biological changes closer to the prodromal phase, before classical motor symptoms become evident.
The challenge for IVD will not be analytical sensitivity alone. It will be demonstrating clinical validity, appropriate patient selection and, above all, clinical utility: when does an earlier result actually change monitoring, referral or treatment?
That is where neurodiagnostics could become one of the most important new frontiers for laboratory medicine.